Analyst Price Targets — NGNE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 9, 2026 10:47 am | Mitchel Kapoor | H.C. Wainwright | $70.00 | $28.60 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Neurogene (NGNE) |
| June 3, 2026 11:04 am | — | UBS | $70.00 | $26.14 | TheFly | Neurogene initiated with a Buy at Rodman & Renshaw |
| April 28, 2026 10:09 am | — | Guggenheim | $69.00 | $27.05 | TheFly | Neurogene initiated with a Buy at Guggenheim |
| October 2, 2025 5:33 pm | — | H.C. Wainwright | $45.00 | $20.61 | TheFly | Neurogene looks 'deeply undervalued' after Taysha news, says H.C. Wainwright |
| April 14, 2025 11:53 am | Keith Tapper | BMO Capital | $16.00 | $10.89 | TheFly | Neurogene price target lowered to $16 from $45 at BMO Capital |
| March 25, 2025 11:01 am | Joel Beatty | Robert W. Baird | $38.00 | $14.20 | TheFly | Neurogene price target lowered to $38 from $46 at Baird |
| March 25, 2025 10:32 am | Mitchell Kapoor | H.C. Wainwright | $50.00 | $14.20 | TheFly | Neurogene price target lowered to $50 from $55 at H.C. Wainwright |
| November 20, 2024 9:53 pm | Paul Matteis | Stifel Nicolaus | $46.00 | $15.33 | StreetInsider | Neurogene (NGNE) PT Lowered to $46 at Stifel |
| November 19, 2024 9:02 pm | Keith Tapper | BMO Capital | $45.00 | $35.59 | StreetInsider | Neurogene (NGNE) PT Lowered to $45 at BMO Capital |
| November 12, 2024 2:09 pm | Keith Tapper | BMO Capital | $60.00 | $64.48 | StreetInsider | Neurogene (NGNE) PT Lowered to $60 at BMO Capital |
Latest News for NGNE
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 96,450 shares of the Company's common stock to six new…
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the pricing of its previously announced public offering of 3,500,000 shares of its common stock at a public offering price per share of $30.00 and, in lieu of common stock to certain investors, pre-funded…
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it has commenced a public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In…
Neurogene Inc. (NGNE) Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome Transcript
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NGNE.
U.S. House Trading
No House trades found for NGNE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.